Table of Contents
ISRN Gastroenterology
Volume 2011 (2011), Article ID 201529, 4 pages
http://dx.doi.org/10.5402/2011/201529
Case Report

Acalculous Cholecystitis in a Patient with Hepatocellular Carcinoma on Sorafenib

Second Department of Internal Medicine, Wakayama Medical University, 811-1 Kimiidera Wakayama City, Wakayama 641-0012, Japan

Received 9 October 2010; Accepted 4 November 2010

Academic Editor: A. A. te Velde

Copyright © 2011 Mariko Sanda et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. S. Chang, J. Adnane, P. A. Trail et al., “Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models,” Cancer Chemotherapy and Pharmacology, vol. 59, no. 5, pp. 561–574, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. S. M. Wilhelm, C. Carter, L. Tang et al., “BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis,” Cancer Research, vol. 64, no. 19, pp. 7099–7109, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. J. M. Llovet, S. Ricci, V. Mazzaferro et al., “Sorafenib in advanced hepatocellular carcinoma,” New England Journal of Medicine, vol. 359, no. 4, pp. 378–390, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. A. L. Cheng, Y. K. Kang, Z. Chen et al., “Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial,” Lancet Oncology, vol. 10, no. 1, pp. 25–34, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. G. de Lima Lopes Jr. and C. M. Rocha Lima, “Emphysematous cholecystitis in a patient with gastrointestinal stromal tumor treated with sunitinib,” Pharmacotherapy, vol. 27, no. 5, pp. 775–777, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. G. Gomez-Abuin, A. A. Karam, N. A. Mezzadri, and C. A. Bas, “Acalculous cholecystitis in a patient with metastatic renal cell carcinoma treated with sunitinib,” Clinical Genitourinary Cancer, vol. 7, no. 1, pp. 62–63, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. S. Kalliafas, D. W. Ziegler, L. Flancbaum, and P. S. Choban, “Acute acalculous cholecystitis: incidence, risk factors, diagnosis, and outcome,” American Surgeon, vol. 64, no. 5, pp. 471–475, 1998. View at Google Scholar · View at Scopus
  8. J. Y. Kang and R. C. N. Williamson, “Cholecystitis without gallstones,” HPB Surgery, vol. 2, no. 2, pp. 83–103, 1990. View at Google Scholar · View at Scopus
  9. J. K. Ryu, K. H. Ryu, and K. H. Kim, “Clinical features of acute acalculous cholecystitis,” Journal of Clinical Gastroenterology, vol. 36, no. 2, pp. 166–169, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Andry, A. D. Turnbull, J. Botet, and R. C. Kurtz, “Cholesonographic characteristics of cystic duct metastasis causing acute acalculous cholecystitis: case report,” Journal of Surgical Oncology, vol. 31, no. 3, pp. 178–181, 1986. View at Google Scholar · View at Scopus
  11. K. T. Barnett and M. P. Malafa, “Complications of hepatic artery infusion: a review of 4580 reported cases,” International Journal of Gastrointestinal Cancer, vol. 30, no. 3, pp. 147–160, 2001. View at Google Scholar · View at Scopus
  12. B. Shpitz, A. Sigal, Z. Kaufman, and A. Dinbar, “Acute cholecystitis in diabetic patients,” American Surgeon, vol. 61, no. 11, pp. 964–967, 1995. View at Google Scholar · View at Scopus
  13. H. X. Chen and J. N. Cleck, “Adverse effects of anticancer agents that target the VEGF pathway,” Nature Reviews Clinical Oncology, vol. 6, no. 8, pp. 465–477, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. F. Elice, F. Rodeghiero, A. Falanga, and F. R. Rickles, “Thrombosis associated with angiogenesis inhibitors,” Best Practice and Research: Clinical Haematology, vol. 22, no. 1, pp. 115–128, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. K. R. Stenmark, K. A. Fagan, and M. G. Frid, “Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms,” Circulation Research, vol. 99, no. 7, pp. 675–691, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus